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Introduction
The mammalian prion protein PrPC is a GPI anchored membrane 
protein associated with the outer leaflet of the cell cytosolic mem-
brane.1 It is central to the spongiform encephalopathies which are 
protein misfolding diseases of inherited, sporadic, iatrogenic or 
zoonotic origin.2,3 Disease is marked by the conversion of PrPC to 
a misfolded isoform, PrPSc, and is typically associated with amy-
loid plaque formation, neurodegeneration and brain spongiosis. 
However, cases in which high levels of PrPSc occur without clini-
cal disease4 or without the hallmark protease resistant PrP27–30 
core of PrPSc have been also described5,6 leading to the suggestion 
that the neurotoxic species is an intermediate isoform on the fold-
ing pathway between PrPC and PrPSc.7 Toxicity experiments using 
artificially assembled PrPSc fibrils in vitro have suggested that tox-
icity resides in small oligomeric species,8 an off-pathway interme-
diate to the formation of fibrillar PrPSc,9 plausibly explaining the 
uncoupling of infectivity from PrPSc titer and pathogenicity in 
some cases.10
At the molecular level, a hydrophobic span of residues 
(HP) within the region 105–125 of the intrinsically disordered 
N-terminus of PrPC has been shown to mediate pathogenicity 
in vitro and in vivo and a peptide comprising the PrPC sequence 
106–126 exhibits conditional toxicity when added to neuronal 
cell lines expressing WT PrPC.11 Further, transgenic mice hetero-
zygous for a PrPC gene encoding a deletion of the HP sequence 
(PrP Δ105–125) display a neonatally lethal phenotype that is 
rescued by the overexpression of WT PrPC.12,13 WT PrPC and 
PrP Δ105–125 have comparative expression levels in cell culture 
and both localize to the outer leaflet of the cytosolic membrane 
suggesting that the toxicity of PrP Δ105–125 is not due to insta-
bility within the cell.14 Instead, a mechanism has been proposed 
in which the deleterious effects of PrP Δ105–125 are rescued by 
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PrPC WT through competition for a common membrane surface 
receptor that may mediate inward pro/anti-apoptotic signaling 
dependant on the PrPC isoform that is bound. Thus, PrP Δ105–
125 could subvert normal function to mediate pathogenicity.15
An alternative model of PrP Δ105–125 toxicity has also been 
described in which PrP Δ105–125 facilitates spontaneous inward 
ionic currents that are absent in cell lines expressing WT PrPC 
alone and are suppressed by its co-expression.16 Both models sug-
gest that PrP Δ105–125 adopts a different conformation to that 
of WT PrPC and this is supported in part by available biochemical 
and biophysical measurement.17 To explore further the conforma-
tional properties of PrP Δ105–125 compared with PrPC WT an 
extended set of deletion mutants in the hydrophobic region of 
murine prion protein were constructed and the resulting proteins 
subjected to comparative biophysical analyses following expres-
sion and purification.
Results
To probe the role of residues 105–125 in PrPC conformation, a 
series of overlapping deletions was constructed in the context of 
mouse PrPC (NM_011170) (Fig. 1A) and the resulting sequences 
expressed as His tagged proteins in E. coli. Each protein could be 
purified to homogeneity by a combination of differential solu-
bility and metal chelate chromatography (Fig. 1B). Following 
refolding all PrPC variants were found to be soluble and suit-
able for a low resolution structural probe analysis using the 
environmentally sensitive fluorescent dye 1-anilinonaphthalene 
8-sulfonate (ANS) to assess the solvent accessibility of hydropho-
bic residues.18-20 As PrPC is a Cu2+ binding protein.21-23 ANS mea-
surements were performed in the presence and absence of 50 μM 
CuSO
4
. The observed ANS fluorescence was found to be inversely 
proportional to the extent of the deletion introduced with the 
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PrP 90–231 (representing a negative 
control for Cu2+ binding as it lacks 
the octarepeats) were assayed for ANS 
binding in a pH range from 3–7 in 
the presence and absence of Cu2+ as 
before. Lowering the pH led to an 
increase in solvent exposed hydropho-
bic residues for all constructs tested 
but Δ105–125 displayed the highest 
overall ANS fluorescence across the 
pH range (Fig. 2B). The presence of 
Cu2+ ions lowered ANS florescence for 
all constructs to a value pH 5 as before 
(compare Fig. 2A) but below pH 5 
ANS fluorescence markedly increased, 
suggesting general unfolding.
To assess whether the increased 
ANS fluorescence of PrP Δ105–125 
compared with WT 23–231 was also 
associated with a change in overall 
structure as reflected by epitope acces-
sibility to a number of monoclonal 
antibodies (mAbs), each refolded 
protein was assessed by compara-
tive ELISA with the anti-prion mAbs 
6D11,28 7H6,29 6H4,30 8H4 and 
9H7,29 none of which have published 
epitopes within the deleted region 
(Fig. 3A). All mAbs bound similarly 
to each protein with the exception 
of 7H6 which failed to bind appre-
ciably to Δ105–125 (Fig. 3B). The 
epitope for 7H6 has been reported to 
lie within residues 130–14029 which, 
of all the mAbs tested, is the epit-
ope closest to the region deleted in 
Δ105–125 so the possibility that 
binding to the epitope is affected by 
its proximity to the deleted sequence 
cannot be excluded. Overall however, 
there was no evidence for a substantial 
change in accessibility to the poly-
peptide backbone of Δ105–125 as 
measured by antibody binding. Circular dichroism (CD) spec-
troscopy was used to probe the secondary structure of each puri-
fied deletion mutant after normalization of protein concentration 
and the obtained spectra were deconvoluted using the K2D3 
algorithm.31 The deletion mutants generally gave weaker CD 
spectra than WT 23–321 and PrP 90–231 but a discernible trend 
was that the strength of the spectral signal was inversely corre-
lated with the extent of the deletion suggesting that the intrin-
sically disordered region contributes to the defined secondary 
structural elements of the folded C-terminus of PrPC. The calcu-
lated secondary structural content of most deletion mutant was 
comparable to that of WT 23–231 but, uniquely, PrP Δ105–125 
notable exception of the Δ105–125 construct which displayed a 
fluorescence value similar to that of WT 23–231 (Fig. 2A). The 
same relative ANS fluorescence was observed when all samples 
were measured in the presence of Cu2+ although the levels were 
lower overall, consistent with Cu2+ bound PrP molecules adopt-
ing a more compact fold and allowing less access to hydrophobic 
residues.24,25
The novel hydrophobic solvent accessibility of PrPC Δ105–125 
in relation to the other deletion mutants was explored further. 
As copper loading of PrPC leads to its endocytosis and traffick-
ing to early endosomes22,23,26 where the pH is more acidic,27 the 
instability of PrP Δ105–125 in acidic pH might contribute to 
its observed toxicity. Thus, PrP Δ105–125, WT 23–231 and 
Figure 1. Design and expression of prion deletion mutants. (A) schematic representation of murine 
PrP constructs. The N-terminal basic region is between amino acids 23 and 31. The five octarepeats are 
between amino acids 51 and 90. The charged cluster upstream of the hydrophobic region is indicated 
by the box between amino acids 95 and 105. The neurotoxic hydrophobic region is boxed between 
amino acids 105 and 125. Beta sheets 1 and 2 are labeled s1 and s2, and helices 1, 2 and 3 as h1, h2 
and h3 respectively. Balls on sticks represent the glycosylation sites at asn 180 and asn 196. The disul-
phide bridge linking helicies 2 and 3 at cys 179 and cys 214 is shown as s-s. (B) sDs-PaGe analysis of all 
purified prion proteins. Lane 1, PrP 90–231; lane 2, PrP 23–231; lane 3, PrP Δ95–105; lane 4, PrP Δ95–125; 
lane 5, PrP Δ95–135; lane 6, PrP Δ105–125; lane 7, PrP Δ105–135; lane 8, 5 μg of Bsa. Numbers to the left 
in (B) are molecular mass markers and are in kilodaltons (kDa).
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1-palmitoyl-2-oleoyl-sn-glycero-3-phosphocholine (PC) were 
incubated with each protein and the mixtures subjected to flota-
tion assay. POPG and RNA have been shown previously to be the 
minimum components necessary for the formation of PrPSc de 
novo from recombinant PrPC 34 while membranes formed of PC 
mimic, to some extent, the cytosolic membrane. Gradients were 
fractionated from the top and the presence of each protein deter-
mined by ELISA using mAb 6H4. Both WT 23–231 and PrP 
90–231 interacted with POPG as evidenced by their presence 
in the lower density fractions 1–3 but not with PC vesicles while 
Δ105–125 showed no binding to either POPG or PC vesicles (Fig. 
5). To investigate if membrane binding influenced membrane 
stability following binding, WT 23–231, PrP 90–231 and PrP 
Δ105–125 were also incubated with POPG vesicles loaded with 
carboxyfluorescein. The inclusion of WT 23–231 had a substan-
tial effect on vesicle integrity, causing nearly complete dye release 
at a concentration of 1 μM whereas membrane destabilization 
by PrP 90–231 required a 10-fold higher concentration (Fig. 6) 
and Δ105–125 showed no membrane destabilization activity, in 
agreement with the strength of vesicle binding. None of the other 
internally deleted prion constructs caused dye release consistent 
with a lack of membrane binding (not shown).
Discussion
Residues in the hydrophobic core of the mouse prion protein 
are associated with the revelation of direct toxicity in vivo12,13 
and in vitro.11 Here, the consequence of deletion of these resi-
dues on prion protein structure and function was investigated. 
Following expression and purification, ANS binding in vitro 
suggested that deletion of the hydrophobic residues leads to a 
reduction in solvent accessible binding sites, with the extent of 
showed a reduction in α helix and a concomitant increase in β 
sheet (Table 1).
To test whether the unique properties of construct Δ105–125 
were dependent on the expression system used, all deletion con-
structs were also expressed as GFP fusion proteins in insect cells 
using recombinant baculoviruses.32 Fusion to GFP has been 
shown to provide a measure of the folding and stability of the 
tagged protein or protein domain.33,34 Following the construc-
tion of recombinant baculoviruses, high titer stocks were used 
to infect Sf9 cells at high multiplicity and the expression level of 
each prion-GFP fusion was assessed by western blot with mAb 
6H4 (Fig. 4A). In addition, GFP fluorescence was measured by 
flow cytometry and the mean fluorescence plotted after normal-
ization to the intensity of the 6H4 signal. All prion-GFP fusion 
proteins were expressed at significant levels as detected by west-
ern blot and all bar PrP Δ105–125 showed similar levels of fluo-
rescence. However, PrP Δ105–125-GFP showed a lower relative 
fluorescence than all other constructs including the full-length 
protein (Fig. 4B). When cells expressing WT 23–231-GFP and 
PrP Δ105–125-GFP were examined at the single cell level, those 
expressing WT 23–231-GFP fusion showed abundant fluores-
cence evenly distributed throughout the cytoplasm while those 
expressing PrP Δ105–125 were more heterogeneous with exam-
ples of punctate fluorescence, often sequestered at the poles of 
the cell (Fig. 4C). These data are consistent with PrP Δ105–125 
exhibiting an altered degree of stability and routing following 
expression in insect cells.
As prion amino acids 105–125 are reported to associ-
ate with lipids,17 purified WT 23–231, PrP 90–231 and 
PrP Δ105–125 proteins were tested for binding to syn-
thetic lipids in vitro. Vesicles formed with 1-palmitoyl-
2-oleoyl-sn-glycero-3-phospho-(1'-rac-glycerol) (POPG) or 
Figure 2. aNs fluorescence. (A) each prion construct was refolded and assessed for aNs binding in the presence and absence of cu2+. The concentra-
tion of proteins was 35 μM, the aNs concentration 600 μM and the cu2+ concentration 50 μM. all readings were normalized to control measurement 
of buffer with aNs alone. Measurements were performed in triplicate and error bars indicate the standard error mean. (B) The effect of ph on aNs 
fluorescence for WT 23–231 (circle), Δ105–125 (square) and 90–231 (diamond). The filled symbols/solid lines are aNs data in the absence of cu2+ while 
the open symbols/dashed lines are aNs data in the presence of cu2+. The assay conditions were as above with the exception that the ph was indepen-
dently buffered in each case. experiments were performed in triplicate and error bars indicate the standard error mean.
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23–231, suggesting that Δ105–125 adopts a unique conforma-
tion in which ANS binding to alternate residues compensates 
for those lost by deletion. Interestingly, construct PrP 90–231 
also displayed significantly reduced fluorescence suggesting that 
ANS binding occurs either largely in the region 23–89 or that 
deletion of amino acids 23–89 stabilizes the folding of residues 
90–231, as suggested by the fact that the available structures 
of PrP solved by high resolution NMR35-37 or X-ray crystallog-
raphy38,39 required similar truncations. The ANS fluorescence 
shown by the internally deleted PrP proteins was reduced in the 
presence of Cu2+ ions. Cu2+ binds with high affinity in vitro to 
the octarepeats region40 and to a further site consisting of His 
96 and His 111.21 Copper is also associated with PrPC in vivo.41,42 
Reduced ANS binding in the presence of copper would be con-
sistent with reduced solvent accessibility caused by compaction 
of the tertiary structure, consistent with the in vitro observa-
tions that Cu2+ reduces PrPC aggregation and fibrillization.9 All 
constructs displayed significantly higher ANS signal at acidic 
pH, with Δ105–125 displaying the greatest increase compared 
with WT suggesting that its novel structure may also have an 
increased sensitivity to pH dependent unfolding. This may be 
the deletion broadly correlated with the reduction observed, 
i.e., PrP Δ95–105 displayed the smallest reduction and PrP 
Δ105–135 the largest. The deleted hydrophobic residues are 
disordered in the available NMR structures35,36 and are there-
fore likely to be solvent accessible. Thus, deletion would be 
expected to reduce solvent accessibility and ANS signal, broadly 
as observed. Uniquely however, PrP Δ105–125 was exempt from 
this trend and demonstrated equivalent fluorescence to WT 
Figure 3. Monoclonal antibody probing of local structure. (A) The epitope locations of each of 5 mabs used in the study drawn on a schematic of the 
prion protein structure, the N-terminus is omitted for clarity. (B) comparative eLIsa of WT 23–231 and Δ105–125 with each of the mabs shown. each 
protein antigen was normalized to 5 μM before coating to the plate.
Table 1. cD spectroscopy of purified prion proteins after analysis of α 
helix and β sheet content using the K2D3 algorithm
Construct α-Helix β-Sheet
90–231 81.1 0.4
23–231 66.5 1.1
Δ95–105 68.7 1.8
Δ95–125 62.9 1.7
Δ95–135 62.5 1.9
Δ105–125 56.8 8.5
Δ105–135 64.4 1.5
www.landesbioscience.com Prion 239
WT 23–231 and PrP 90–231 binding to synthetic membranes 
also lead to loss of vesicle integrity, although the absence of 
residues 23–89 reduced the efficiency of membrane destabili-
zation significantly. Prion protein residues 105–125 have been 
demonstrated to facilitate POPG interaction17 in the context of 
full length protein, although an isolated peptide consisting of 
residues 105–126 fails to bind membranes,47 suggesting con-
text dependency in membrane interaction for this sequence. 
Membrane pore formation as a mechanism of toxicity for PrP 
Δ105–125 may require the higher complexity of biological 
membranes.
The unique structural properties of PrP Δ105–125, mea-
sured here by a variety of assays, would be consistent with the 
receptor mediated hypotheses models for prion toxicity. The 
NMDA receptor has been identified recently as an interaction 
partner of PrPC,48-51 leading to the speculation that the particu-
lar conformation adopted by Δ105–125 is the conformation that 
binds the NMDA receptor and mediates a toxic signaling out-
come. Alternatively, residues 95–125 mediate, in concert with 
the extreme N terminus residues 23–31 and the length of the 
intervening sequence, the ability of PrPC to bind to amyloid-β.52 
Particular loss of 95–125 could therefore prevent the formation 
of the specific structure associated with amyloid-β binding and 
mediate toxicity directly. Further studies of membrane binding 
and direct interaction with NMDA-R, amyloid-β and PrPSc may 
help to relate the molecular properties of PrP residues 105–125 
with the mechanism of prion associated pathology.
Materials and Methods
All chemical reagents were purchased from Sigma Aldrich unless 
otherwise stated. Lipids were obtained from Avanti polar lipids. 
Restriction enzymes were purchased from New England Biolabs 
(NEB) and used in accordance with manufactures guidelines. 
of physiological significance as the protein is normally trafficked 
to the endosome.27 As with ANS binding at neutrality, increased 
ANS fluorescence at lower pH was mitigated by the presence of 
Cu2+ ions.
A novel tertiary structure for Δ105–125 compared with other 
internally deleted constructs was supported by CD analysis 
which revealed an altered α helix/β sheet ratio when compared 
with all other constructs. This is consistent with the data of 
Thaa et al. who showed that a similar mutant, deleted for resi-
dues Δ111–114, had increased β sheet content when compared 
with WT 23–231.43 Monoclonal antibody binding showed that 
Δ105–125, unlike WT 23–231, had lost the ability to bind 
mAb 7H4 despite the retention of the mapped epitope (residues 
130–140).29 In the structure of PrP this region encompasses the 
first β strand, upstream of helix 1, and the observed increase in 
β sheet content could be due to remodeling of the sheet in this 
region which obscures the 7H4 epitope. However, confirma-
tion of this would require finer structural probing, for example 
by twin site ELISAs, to assess local conformation. Most mAb 
binding to WT 23–231 and Δ105–125 was equivalent suggest-
ing little overall change to the protein fold unlike that observed 
for truncated forms of PrP.44 Δ105–125 also exhibited singular 
behavior when tagged with GFP and expressed in in Sf 9 cells as 
a PrP Δ105–125-GFP fusion protein. Fluorescence was reduced 
overall and had a punctate rather than dispersed pattern, as was 
shown by WT 23–231. This data are consistent with that of 
Christensen et al. who concluded that although a PrP mutant 
lacking residues 95–125 localized to the cytosolic membrane in 
a variety of mammalian cells, it was prone to increased aggrega-
tion when measured by analytical centrifugation.44 The direct 
toxicity of PrP Δ105–125 in vivo has been suggested to depend 
on pore formation in cytosolic membranes.16,45 However only 
PrP 90–231 and WT 23–231 were able to interact with anionic 
POPG membranes in vitro, consistent with previous studies.17,46 
Figure 4. expression of prion deletions in Sf9 cells as fusion proteins with GFP. (A) Western blot of Sf9 cells infected with each prion-GFP fusion with 
mab 6h4 at 2 d post infection. (B) Mean fluorescence of each prion-GFP fusion at 2 d post infection normalized to the 6h4 signal. (C) Fluorescence mi-
croscopy of Sf9 cells expressing GFP tagged prion protein. The upper panel is WT 23–231-GFP and the lower is Δ105–125-GFP. The scale bars indicate 
400 μm.
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buffer (8 M Urea, 10 mM TRIS-HCl pH 7.5, 1 mM DTT). 
Expressed protein was purified by affinity chromatography on 
a 5 ml His Trap FF column (GE Healthcare). Eluted peak frac-
tions were pooled and concentrated to 2.5 ml by centrifugation 
at 2,500 × g at 4°C using a Vivaspin concentrator (10,000 MW, 
Sartorius). Concentrated protein was desalted using PD10 col-
umns (GE Healthcare) pre-equilibrated in solubilization buffer. 
By SDS-PAGE gel analysis each recombinant protein was > 99% 
pure and protein stocks were stored at 4°C.
Refolding of recombinant prion proteins. Purified protein 
samples denatured in solubilisation buffer were refolded by serial 
dilution in Chelex-100 (Sigma Aldrich) treated 10 mM TRIS-
HCl pH 7.5, 1 mM DTT. The concentration of each refolded 
protein was determined using the Beer Lambert equation.
CD spectroscopy. Protein samples were refolded as described 
and normalized to 0.5 mg ml−1. Samples were analyzed under 
nitrogen using a 1 mm path length quartz cuvette in a Chirascan 
Circular Dichroism Spectrometer (Applied Photophysics). Scans 
were from 200 nm to 280 nm with 1 nm intervals. Four scans 
per sample were performed at room temperature (21°C) and were 
normalized to the scan of buffer alone, then averaged.
Pfu turbo polymerase was purchased from Stratagene and used 
similarly.
Cloning of deletion mutant constructs. A pET23a vector 
containing the cloned cDNA of residues 23–231 of murine prion 
protein was amplified with Pfu Turbo (Stratagene) by outfac-
ing PCR using primers that contained unique terminal HindIII 
sites. The resultant PCR products were subsequently digested 
with HindIII, isolated by gel extraction and self-ligated using 
T7 DNA ligase (NEB). Ligation reactions were transformed into 
Novablue chemically competent E. coli (Novagen) and plasmid 
DNA extracted and screened by digestion with HindIII. Putative 
constructs were verified by sequencing (Source Bioscience). 
C-terminally GFP tagged constructs were created by explanting 
each deleted construct in-frame into a pTriEx vector continuing 
a GFP tag.53
Expression and purification of recombinant prion proteins. 
Purified recombinant murine prion protein was produced as 
described.25 Briefly pET23a construct protein expression was 
induced at 37°C in LB when cultures were at an OD
600
 of 0.6 
using IPTG at 0.2 mM and grown for a further 3 hrs. Cells 
were harvested by centrifugation at 2,500 × g for 20 min at 4°C. 
Pellets were lysed with lysozyme and solubilized in solubilization 
Figure 5. Binding to synthetic lipids. eLIsa data for binding of 6h4 to each fraction of a sucrose gradient following flotation assay. Purified prion 
proteins WT 23–131, 90–231 and Δ105–125 were incubated with POPG (solid lines) or Pc (dashed lines) vesicles as described, prior to underloading 
the gradient. The samples were: WT 23–231 with no lipid (◆), WT 23–231 with Pc (■), WT 23–231 with POPG (▲), Δ105–125 with Pc (x), Δ105–125 with 
POPG (□) and 90–231 with POPG (●). 93–231 with Pc was not done. Fraction 1 represents the top and fraction 8 the bottom of the gradient. eLIsa 
measurements were performed in triplicate and error bars indicate the standard error mean.
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μl of tetramethylbenzidine (Europa Bioproducts) was added to 
each well. The reaction was stopped by addition of 50 μl of 0.1 
M H
2
SO
4
 and the absorbance of each well at 440 nm was mea-
sured using a GENios plate reader (Tecan). Experiments were 
performed in triplicate. Controls had no protein or no primary 
antibody added and the absorbance readings were normalized to 
the reading for no protein.
Western blotting. Protein samples were separated on pre-cast 
Any kD TRIS-HCl SDS-polyacrylamide gels (Bio-Rad) and 
transferred onto Immobilon-P transfer membrane (Millipore) 
using semi dry transfer. Membranes were blocked by incuba-
tion in 5% milk powder in TBST (50 mM Tris.HCl pH 7.5, 
150 mM NaCl, 0.05% Tween 20) for 1 h. at room temperature. 
The membrane was washed with TBST and incubated with 
0.5 μgs/ml mAb 6H4 (Prionics) in a 0.5% casein TBST solution 
(diluent) for 1 h. After two 10 min washes with TBST the blot 
was incubated with 1:1,000 anti-mouse IgG peroxidase conjugate 
(Sigma) in diluent for 1 h. The membrane was washed twice for 
10 min with TBST and the bound conjugate detected using ECL 
(Amersham Biosciences). Band intensities were measured using 
Quantiscan (BioSoft).
FACS analysis. Recombinant baculoviruses were generated 
and amplified to high titer stocks as described.53 Spodoptera 
frugiperda 9 (Sf9) monolayers of 0.9 × 106 cells were infected 
8-anilino-1-naphthalene sulfonate (ANS) fluorescence. 
Purified prion protein constructs were refolded as described and 
adjusted to a concentration of 70 μM. 50 μl of each protein solu-
tion was added to the well of a flat bottomed black 96-well plate 
(Greiner) to which 50 μl of 1.2 mM ANS in the same buffer 
was added and mixed. For Cu2+ containing experiments CuSO
4
 
solution was added to the refolded protein to a cation concentra-
tion of 100 μM. After incubating for 5 min at room temperature 
fluorescence was read with a GENios plate reader (Tecan) using 
an excitation wavelength of 360 nm and emission of 465 nm. 
Experiments were done in triplicate and results normalized to a 
control in which ANS was added to appropriate buffer lacking 
protein.
ELISA. Proteins were refolded as described and normalized to 
5 μM. Samples were absorbed onto flat bottomed transparent 96 
well plates (Nuncalon II) by incubating for 1 h at room tempera-
ture in 0.1 M NaHCO
3
. Wells were then washed with TBS and 
blocked by filling with 5% Casein in TBST and incubating 16 h 
at 4°C. Wells were then washed with TBS and incubated for 1 h 
with 50 μl of the appropriate primary antibody at 1 μg/ml dilu-
tion in a solution of 0.5% Casein, TBST. After washing 3 times 
with TBS, the wells were incubated for 1 h with 50 μl of 1:1,000 
dilution of anti-Mouse IgG peroxidase conjugate (Sigma) in 
0.5% casein TBST. Wells were washed 3 times in TBS and 50 
Figure 6. Fluorescence dequenching of cF loaded vesicles by prion protein binding. The initial concentration of each protein was 10 μM. The concen-
tration of lipid remained constant over the dilution series at 250 μg/ml. The samples were: WT 23–231 (◆), 90–231 (■) and Δ105–125 (x). Measurements 
were performed in triplicate and error bars indicate the standard error mean.
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gradient of 60%:10% sucrose in 20 mM Tris.HCl pH 7.4, 100 
mM NaCl. Gradients were developed in a TL-100 ultra-centrifuge 
(Beckman) at 50,000 rpm for three hours at 4°C. The gradients 
were fractionated from the top and the fractions absorbed to the 
wells of a Nuncalon II ELISA plate. ELISA was done as described. 
The experiments were performed in triplicate and signals were 
normalized to that of a control gradient with protein alone.
CF Vesicle dye release assay. CF loaded vesicles were diluted to 
500 μg/ml lipid. One hundred microliters of diluted vesicles was 
mixed with 100 μl of refolded protein in the well of a fluorotrac 
flat bottomed black plate (Greiner) and incubated for 5 min at 
room temperature. The fluorescence increase upon incubation 
with protein was measured using a GENios plate reader (Tecan) 
using excitation and emission wavelengths of 485 nm and 535 
nm respectively. Controls of total and no CF dye were measured 
by incubating 100 μl of diluted vesicles with 100 μl of buffer 20 
mM Tris.HCl pH 7.4, 100 mM NaCl alone (no dye release) or 
100 μl of 1% triton X-100 (total dye release). Measurements were 
performed in triplicate. The fraction of CF dye release at various 
protein concentrations was calculating by using the equation Rf 
= (FPro − F0)/(Ftotal − F0) where Rf is the release factor, FPro is 
the fluorescence reading at a specific protein concentration, F0 is 
the fluorescence reading for the no dye release control and Ftotal 
is the fluorescence reading for the total dye release control.
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at an MOI > 3 and incubated for 2 d at 28°C. Cells were 
removed from the plate and the resultant pellet washed twice 
before being resuspended in 2.5 ml of FACSFlow (Becton 
Dickenson). Fluorescence was measured using a FACScan 
(Becton Dickinson).
Fluorescence microscopy. Sf9 cells were infected as described 
for FACS analysis and GFP fluorescence was observed using 
an EVOS inverted fluorescence microscope (AMG) at 2 d post 
infection.
Large Unilamellar Vesicle (LUV) production. Five mil-
ligrams of lipid in chloroform was dried using a mini rotary 
vacuum for 2 h. The dried lipid films were then re-hydrated in 
20 mM Tris.HCl pH 7.4, 100 mM NaCl to a concentration of 
5 mg ml−1. One milliliter of the aqueous lipid suspension was 
then extruded 10 times using a Lipofast vesicle extruder (Avanti 
polar lipids) using a 100 nm pore poly carbonate membrane 
resulting in a 100 nm vesicle suspension at a concentration of 
5 mg ml−1 of lipid. Vesicles were confirmed for size and unifor-
mity by EM. Vesicle stocks were kept at 4°C and used within 
1 week of generation.
Carboxyfluorescein (CF) loaded vesicle production. Vesicles 
were prepared as before except the rehydration used a buffer of 
50 mM CF in 20 mM Tris.HCl pH 7.4. Size exclusion chro-
matography with Sephadex G-75 in 20 mM Tris.HCl pH 7.4, 
100 mM NaCl was used to remove excess un-entrapped CF from 
the CF loaded vesicles. CF loaded vesicles were kept at 4°C and 
used within one week of generation.
Vesicle binding assay. Refolded prion protein was incubated 
with POPG or PC lipid vesicles at a protein to lipid ratio of 1:500 
at 37°C for 1 h. The protein lipid mixture was then adjusted to 
60% sucrose w/v and the protein lipid solution layered under a 
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